Spantide I TFA

Names

[ Name ]:
Spantide I TFA

[Synonym ]:
M.W. 1497.80 C75H108N20O13
SPANTIDE
1-Arg-7,9-Trp-11-Leu-substance p
SPANTIDE HYDROCHLORIDE
Spantide I
Substance P-[D-Arg1,D-Trp7,9,Leu11]

Biological Activity

[Description]:

Spantide I, a substance P analog, is a selective NK1 receptor antagonist, with Ki values of 230 nM and 8150 nM for NK1 and NK2 receptor, respectively. Spantide I provides an approach to reduce type 1 and enhance the type 2 cytokine IL-10 in the infected cornea, leading to a significant reduction in corneal perforation[1][2][3].

[Related Catalog]:

Research Areas >> Inflammation/Immunology

Signaling Pathways >> Neuronal Signaling >> Neurokinin Receptor

Signaling Pathways >> GPCR/G Protein >> Neurokinin Receptor

[Target]

NK1:230 nM (Ki)

NK2:8150 nM (Ki)

[In Vivo]

Spantide I (50 and 100 nM perfused through the cerebral ventricles) causes a complete respiratory arrest in all of the examined animals[2]. Spantide I (36 μg/mouse, ip daily) significantly decreases the number of perforated corneas, bacterial counts, and PMNs. Spantide I also downregulates the mRNA levels for type I cytokines (e.g., IFN-γ) as well as MIP-2, IL-6, TNF-α, and IL-1β[3]. Animal Model: Female, 8-week-old C57BL/6 (B6) and BALB/c mice[3]. Dosage: 36 μg/mouse. Administration: IP on days -1 and 0 (day of infection) and daily through 5 days pi (post infection). Result: At 3 and 5 days pi, compound-treated mice had significantly less severe ocular disease than did the PBS-treated mice. Contained significantly fewer PMNs than the corneas of PBS-treated mice at 3 and 5 days pi. Significantly reduced levels of corneal TNF-α mRNA at 3 and 5 days pi. Significantly reduced the level of IL-18 mRNA at 1 day pi.

[References]

[1]. J C Beaujouan, et al. Higher potency of RP 67580, in the mouse and the rat compared with other nonpeptide and peptide tachykinin NK1 antagonists. Br J Pharmacol. 1993 Mar;108(3):793-800.

[2]. M Zubrzycka, et al. Comparison of antagonistic properties of substance P analogs, spantide I, II and III, on evoked tongue jerks in rats. Endocr Regul. 2000 Mar;34(1):13-8.

[3]. Linda D Hazlett, et al. Spantide I decreases type I cytokines, enhances IL-10, and reduces corneal perforation in susceptible mice after Pseudomonas aeruginosa infection. Invest Ophthalmol Vis Sci. 2007 Feb;48(2):797-807.

Chemical & Physical Properties

[ Molecular Formula ]:
C₇₅H₁₀₈N₂₀O₁₃

[ Molecular Weight ]:
1497.79000

[ Exact Mass ]:
1496.84000

[ PSA ]:
548.21000

[ LogP ]:
7.06100

[ Storage condition ]:
-20°C

Safety Information

Articles

Involvement of midbrain tectum neurokinin-mediated mechanisms in fear and anxiety.

Braz. J. Med. Biol. Res. 45(4) , 349-56, (2012)

Electrical stimulation of midbrain tectum structures, particularly the dorsal periaqueductal gray (dPAG) and inferior colliculus (IC), produces defensive responses, such as freezing and escape behavio...

Solution conformation of Substance P antagonists-[D-Arg1, D-Trp7,9, Leu11]-SP, [D-Arg1, D-Pro2, D-Trp7,9, Leu11]-SP and [D-Pro2, D-Trp7,9]-SP by CD, NMR and MD simulations.

Peptides 26 , 875-885, (2005)

Substance P (SP) is an important neuropeptide involved in pain transmission and induction of inflammation. Its antagonists are being extensively investigated for their non-narcotic analgesic and anti-...

Substance P stimulates late-stage rat osteoblastic bone formation through neurokinin-1 receptors.

Neuropeptides 41(1) , 25-31, (2007)

Substance P (SP) is a widely distributed neuropeptide that works as a neurotransmitter and neuromodulator. Recently, SP receptors, particularly neurokinin-1 receptors (NK(1)-Rs) that have a high affin...

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.